By Jake Holdreith
On Monday, March 27, the Supreme Court will hear oral argument in Amgen v. Sanofi, a case with the parties and 27 Amici, including the United States, weighing in on whether and how the Court should address the enablement requirement of Section 112 in the cotext of genus claims, and in particular, genus claims to antibodies in the pharmaceutical sciences.
Related Attorneys
Partner
